Home
Jone Trovik's picture

Jone Trovik

Professor
  • E-mailJone.Trovik@uib.no
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
  • Postal Address
    Postboks 7804
    5020 Bergen
Textbook
  • Show author(s) 2020. Obstetrics and Gynecology. NFOG textbook for medical students. Nordic Federation of Societies of Obstetrics and Gynecology .
Academic article
  • Show author(s) 2021. Cancer awareness in the general population varies with sex, age and media coverage: A population-based survey with focus on gynecologic cancers. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 25-31.
  • Show author(s) 2020. Whole-volume tumor MRI radiomics for prognostic modeling in endometrial cancer. Journal of Magnetic Resonance Imaging. 1-10.
  • Show author(s) 2020. Tumour texture features from preoperative CT predict high-risk disease in endometrial cancer. Clinical Radiology. 1-8.
  • Show author(s) 2020. Prognostic value of the diversity of nuclear chromatin compartments in gynaecological carcinomas. Cancers. 1-16.
  • Show author(s) 2020. Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study. PLoS Medicine.
  • Show author(s) 2020. Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer. European Radiology. 2443-2453.
  • Show author(s) 2020. Maintained survival outcome after reducing lymphadenectomy rates and optimizing adjuvant treatment in endometrial cancer. Gynecologic Oncology. 1-9.
  • Show author(s) 2020. High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer. Gynecologic Oncology. 260-267.
  • Show author(s) 2020. Gynekologiske fistler etter kirurgi og strålebehandling. Tidsskrift for Den norske legeforening.
  • Show author(s) 2020. Early maternal weight gain as a risk factor for SGA in pregnancies with hyperemesis gravidarum: A 15-year hospital cohort study. BMC Pregnancy and Childbirth. 1-10.
  • Show author(s) 2020. Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma. British Journal of Cancer. 1014-1022.
  • Show author(s) 2019. Poor outcome in hypoxic endometrial carcinoma is related to vascular density. British Journal of Cancer. 1037-1044.
  • Show author(s) 2019. Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer. PLOS ONE. 1-13.
  • Show author(s) 2019. PIK3CA amplification associates with aggressive phenotype but not markers of AKT-mTOR signaling in endometrial carcinoma. Clinical Cancer Research. 334-345.
  • Show author(s) 2019. Novel PCDH10-Wnt-MALAT1 regulatory axis in endometrioid endometrial adenocarcinoma. Hong Kong Medical Journal. 17-22.
  • Show author(s) 2019. Incidence of gynecological fistula and its surgical treatment: A national registry-based study. Acta Obstetricia et Gynecologica Scandinavica. 1-7.
  • Show author(s) 2019. Endometrial ablation; Less is more? Historical cohort study comparing long-term outcomes from two time periods and two treatment modalities for 854 women. PLOS ONE. 1-16.
  • Show author(s) 2019. Coping with a disruptive life caused by obstetric fistula: Perspectives from Malawian women. International Journal of Environmental Research and Public Health (IJERPH). 1-14.
  • Show author(s) 2019. Blood steroid levels predict survival in endometrial cancer and reflect tumor estrogen signaling. Gynecologic Oncology. 400-406.
  • Show author(s) 2019. Blood metabolites associate with prognosis in endometrial cancer. Metabolites. 1-15.
  • Show author(s) 2019. Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study. Human Pathology. 90-98.
  • Show author(s) 2018. Preoperative tumor texture analysis on MRI predicts high-risk disease and reduced survival in endometrial cancer. Journal of Magnetic Resonance Imaging. 1637-1647.
  • Show author(s) 2018. Preoperative quantitative dynamic contrast-enhanced MRI and diffusion-weighted imaging predict aggressive disease in endometrial cancer. Acta Radiologica. 1010-1017.
  • Show author(s) 2018. L1CAM expression in uterine carcinosarcoma is limited to the epithelial component and may be involved in epithelial-mesenchymal transition. Virchows Archiv. 591-598.
  • Show author(s) 2018. Identification of nine new susceptibility loci for endometrial cancer. Nature Communications. 1-12.
  • Show author(s) 2018. Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer. PLOS ONE. 1-21.
  • Show author(s) 2018. High expression of the p53 isoform ? is associated with reduced progression-free survival in uterine serous carcinoma. BMC Cancer. 1-10.
  • Show author(s) 2018. Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Medicine. 1978-1987.
  • Show author(s) 2018. Chromatin organisation and cancer prognosis: a pan-cancer study. The Lancet Oncology. 356-369.
  • Show author(s) 2018. Blood steroids are associated with prognosis and fat distribution in endometrial cancer. Gynecologic Oncology. 46-52.
  • Show author(s) 2018. Association Between Proportion of Nuclei With High Chromatin Entropy and Prognosis in Gynecological Cancers. Journal of the National Cancer Institute. 1400-1408.
  • Show author(s) 2018. Asparaginase-like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study. BJOG: An International Journal of Obstetrics and Gynaecology. 1695-1703.
  • Show author(s) 2018. Added value of estrogen receptor, progesterone receptor, and L1 cell adhesion molecule expression to histology-based endometrial carcinoma recurrence prediction models: An ENITEC Collaboration study. International Journal of Gynecological Cancer. 514-523.
  • Show author(s) 2017. Type of vascular invasion in association with progress of endometrial cancer. APMIS - Journal of Pathologiy, Microbiology and Immunology. 1084-1091.
  • Show author(s) 2017. Tumour-microenvironmental blood flow determines a metabolomic signature identifying lysophospholipids and resolvin D as biomarkers in endometrial cancer patients. OncoTarget. 109018-109026.
  • Show author(s) 2017. Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients. OncoTarget. 106989-107001.
  • Show author(s) 2017. Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers. OncoTarget. 68530-68541.
  • Show author(s) 2017. Potential targets' analysis reveals dual PI3K/mTOR pathway inhibition as a promising therapeutic strategy for uterine leiomyosarcomas - An ENITEC group initiative. Clinical Cancer Research. 1274-1285.
  • Show author(s) 2017. PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. Scientific Reports. 1-12.
  • Show author(s) 2017. Long non-coding RNA HAND2-AS1 inhibits invasion and metastasis in endometrioid endometrial carcinoma through inactivating neuromedin U. Cancer Letters. 23-34.
  • Show author(s) 2017. Late-week surgical treatment of endometrial cancer is associated with worse long-term outcome: Results from a prospective, multicenter study. PLOS ONE. 1-12.
  • Show author(s) 2017. In vivo MR spectroscopy predicts high tumor grade in endometrial cancer. Acta Radiologica. 497-505.
  • Show author(s) 2017. High visceral fat percentage is associated with poor outcome in endometrial cancer. OncoTarget. 105184-105195.
  • Show author(s) 2017. HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. British Journal of Cancer. 378-387.
  • Show author(s) 2017. Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions. Gynecologic Oncology. 672-677.
  • Show author(s) 2017. Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients. British Journal of Cancer. 840-847.
  • Show author(s) 2017. Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study. American Journal of Obstetrics and Gynecology. 432.e1-432.e17.
  • Show author(s) 2017. Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions. Gynecologic Oncology. 197-203.
  • Show author(s) 2016. Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer. OncoTarget. 69844-69856.
  • Show author(s) 2016. The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nature Genetics. 848-855.
  • Show author(s) 2016. Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Scientific Reports.
  • Show author(s) 2016. L1CAM expression in endometrial carcinomas: An ENITEC collaboration study. British Journal of Cancer. 716-724.
  • Show author(s) 2016. Integrative protein-based prognostic model for early-stage endometrioid endometrial cancer. Clinical Cancer Research. 513-523.
  • Show author(s) 2016. Incidence of obstetric fistula in Norway: A population-based prospective cohort study. Acta Obstetricia et Gynecologica Scandinavica. 405-410.
  • Show author(s) 2016. Hyperemesis Gravidarum is associated with substantial economic burden in addition to severe physical and psychological suffering. Israel Journal of Health Policy Research.
  • Show author(s) 2016. Genetic risk score mendelian randomization shows that obesity measured as body mass index, but not waist:hip ratio, is causal for endometrial cancer. Cancer Epidemiology, Biomarkers and Prevention. 1503-1510.
  • Show author(s) 2016. Five endometrial cancer risk loci identified through genome-wide association analysis. Nature Genetics. 667-674.
  • Show author(s) 2016. Changes in Chromatin Structure in Curettage Specimens Identifies High-Risk Patients in Endometrial Cancer. Cancer Epidemiology, Biomarkers and Prevention. 61-67.
  • Show author(s) 2016. CYP19A1 fine-mapping and Mendelian randomization: Estradiol is causal for endometrial cancer. Endocrine-Related Cancer. 77-91.
  • Show author(s) 2016. Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival. OncoTarget. 9696-9707.
  • Show author(s) 2016. Androgen receptor as potential therapeutic target in metastatic endometrial cancer. OncoTarget. 49289-49298.
  • Show author(s) 2015. Tumour apparent diffusion coefficient is associated with depth of myometrial invasion and is negatively correlated to tumour volume in endometrial carcinomas. Clinical Radiology. 487-494.
  • Show author(s) 2015. Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses. OncoTarget. 39676-39691.
  • Show author(s) 2015. Preoperative tumor size at MRI predicts deep myometrial invasion, lymph node metastases, and patient outcome in endometrial carcinomas. International Journal of Gynecological Cancer. 459-466.
  • Show author(s) 2015. Norwegian PUQE (pregnancy-unique quantification of emesis and nausea) identifies patients with hyperemesis gravidarum and poor nutritional intake: A prospective cohort validation study. PLOS ONE. 15 pages.
  • Show author(s) 2015. Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. OncoTarget. 1327-1339.
  • Show author(s) 2015. Metabolic tumor volume on 18F-FDG PET/CT improves preoperative identification of high-risk endometrial carcinoma patients. Journal of Nuclear Medicine. 1191-1198.
  • Show author(s) 2015. Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1. Scientific Reports.
  • Show author(s) 2015. Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer. OncoTarget. 10634-10645.
  • Show author(s) 2015. Hyperemesis gravidarum, nutritional treatment by nasogastric tube feeding: A 10-year retrospective cohort study. Acta Obstetricia et Gynecologica Scandinavica. 359-367.
  • Show author(s) 2015. Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. Human Molecular Genetics. 1478-1492.
  • Show author(s) 2015. DNA ploidy in curettage specimens identifies high-risk patients and lymph node metastasis in endometrial cancer. British Journal of Cancer. 1656-1664.
  • Show author(s) 2015. Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer. Endocrine-Related Cancer. 851-861.
  • Show author(s) 2015. Candidate locus analysis of the TERT–CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk. Human Genetics. 231-245.
  • Show author(s) 2015. ATAD2 overexpression links to enrichment of B-MYBtranslational signatures and development of aggressive endometrial carcinoma. OncoTarget. 28440-28452.
  • Show author(s) 2014. Switch in FOXA1 status associates with endometrial cancer progression. PLOS ONE.
  • Show author(s) 2014. Stathmin Protein Level, a Potential Peredictive Marker for Taxane Treatment Response in Endometrial Cancer. PLOS ONE.
  • Show author(s) 2014. Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. Molecular Cancer.
  • Show author(s) 2014. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer. Cancer. 603-610.
  • Show author(s) 2014. Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. European Journal of Cancer. 3003-3010.
  • Show author(s) 2014. Increased microvascular proliferation is negatively correlated to tumour blood flow and is associated with unfavourable outcome in endometrial carcinomas. British Journal of Cancer. 107-114.
  • Show author(s) 2014. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene. OncoTarget. 1052-1061.
  • Show author(s) 2014. High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors. British Journal of Cancer. 78-84.
  • Show author(s) 2014. Growth differentiation factor-15 as biomarker in uterine sarcomas. International Journal of Gynecological Cancer. 252-259.
  • Show author(s) 2014. Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations. Gynecologic Oncology. 599-606.
  • Show author(s) 2014. Candidate locus analysis of the TERT–CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk. Human Genetics. 231-245.
  • Show author(s) 2014. A novel Wnt regulatory axis in endometrioid endometrial cancer. Cancer Research. 5103-5117.
  • Show author(s) 2013. Preoperative anemia, leukocytosis and thrombocytosis identify aggressive endometrial carcinomas. Gynecologic Oncology. 410-415.
  • Show author(s) 2013. Polymorphisms in inflammation pathway genes and endometrial cancer risk. Cancer Epidemiology, Biomarkers and Prevention. 216-223.
  • Show author(s) 2013. Lack of estrogen receptor-alpha is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clinical Cancer Research. 1094-1105.
  • Show author(s) 2013. Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. PLOS ONE. 9 pages.
  • Show author(s) 2013. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. European Journal of Cancer. 3431-3441.
  • Show author(s) 2013. High phospho-stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition. Clinical Cancer Research. 2331-2341.
  • Show author(s) 2013. Dynamic contrast-enhanced MRI in endometrial carcinoma identifies patients at increased risk of recurrence. European Radiology. 2916-2925.
  • Show author(s) 2013. ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas. Modern Pathology. 428-434.
  • Show author(s) 2013. A discordant histological risk classification in preoperative and operative biopsy in endometrial cancer is reflected in metastatic risk and prognosis. European Journal of Cancer. 625-632.
  • Show author(s) 2012. Standard 1.5-T MRI of endometrial carcinomas: modest agreement between radiologists. European Radiology. 1601-1611.
  • Show author(s) 2012. SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer. European Journal of Cancer. 1988-1996.
  • Show author(s) 2012. Revision of FIGO surgical staging in 2009 for endometrial cancer validates to improve risk stratification. Gynecologic Oncology. 103-108.
  • Show author(s) 2012. Magnetic resonance imaging performs better than endocervical curettage for preoperative prediction of cervical stromal invasion in endometrial carcinomas. Gynecologic Oncology. 413-418.
  • Show author(s) 2012. MDM2 Promoter SNP344T>A (rs1196333) Status Does Not Affect Cancer Risk. PLOS ONE. 6 pages.
  • Show author(s) 2012. Loss of GPER identifies new targets for therapy among a subgroup of ER alpha-positive endometrial cancer patients with poor outcome. British Journal of Cancer. 1682-1688.
  • Show author(s) 2012. KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer. British Journal of Cancer. 1997-2004.
  • Show author(s) 2012. Improved survival related to changes in endometrial cancer treatment, a 30-year population based perspective. Gynecologic Oncology. 381-387.
  • Show author(s) 2012. High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated. PLOS ONE.
  • Show author(s) 2012. Genome-wide association study identifies a possible susceptibility locus for endometrial cancer. Cancer Epidemiology, Biomarkers and Prevention. 980-987.
  • Show author(s) 2011. The role of adjuvant chemotherapy in surgical stages I-II serous and clear cell carcinomas and carcinosarcoma of the endometrium a collaborative study. International Journal of Gynecological Cancer. 332-336.
  • Show author(s) 2011. Stathmin Overexpression Identifies High-Risk Patients and Lymph Node Metastasis in Endometrial Cancer. Clinical Cancer Research. 3368-3377.
  • Show author(s) 2011. High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer. British Journal of Cancer. 921-926.
  • Show author(s) 2011. Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nature Genetics. 451-454.
  • Show author(s) 2011. Evolution in endometrial cancer evidence from an immunohistochemical study. International Journal of Gynecological Cancer. 316-322.
  • Show author(s) 2011. Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer. Clinical Cancer Research. 4825-4833.
  • Show author(s) 2009. Plasma calprotectin concentrations in women with endometrial carcinoma. Gynecologic Oncology. 491-495.
  • Show author(s) 2009. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proceedings of the National Academy of Sciences of the United States of America. 4834-4839.
  • Show author(s) 2009. Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting. American Journal of Obstetrics and Gynecology. 603-607.
  • Show author(s) 2008. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 8713-8717.
  • Show author(s) 2007. Gynekologiske fistler til urinveier og tarm. Tidsskrift for Den norske legeforening. 417-420.
Academic lecture
  • Show author(s) 2019. European antiemetic regulations (restricting metoclopramide use) increases admission rates due to hyperemesis gravidarum.
  • Show author(s) 2015. Preoperative tumor texture at MRI predicts deep myometrial invasion and non-endometrioid subtype in endometrial carcinomas.
Reader opinion piece
  • Show author(s) 2015. Kvantifisering av svangerskapskvalme :. Tidsskrift for Den norske legeforening. 1018-1019.
  • Show author(s) 2014. Ikke "bare" svangerskapskvalme. Tidsskrift for Den norske legeforening. 430-430.
  • Show author(s) 2012. Stratification based on high tumour cell content in fresh frozen tissue promotes selection of aggressive endometrial carcinomas. Histopathology. 516-519.
  • Show author(s) 2010. Stathmin is superior to AKT and phospho-AKT staining for the detection of phosphoinositide 3-kinase activation and aggressive endometrial cancer. Histopathology. 641-646.
Doctoral dissertation
  • Show author(s) 2012. Endometrial cancer; can biomarkers aid in the prediction of aggressive disease? A study with focus on preoperative tumour markers.
Interview
  • Show author(s) 2014. - Alle kvinner bør ta denne vaksinen.
Abstract
  • Show author(s) 2013. FOXA1 LOSS IN ENDOMETRIAL CANCER IS ASSOCIATED WITH POOR PROGNOSIS AND ER ALPHA LOSS. International Journal of Gynecological Cancer. 1 pages.
  • Show author(s) 2012. Estrogen receptor a loss in endometrial carcinoma is associated with epithelial-to-mesenchymal transition and a potential for PI3Kinase inhibition. Virchows Archiv. 18-18.
  • Show author(s) 2012. Estrogen receptor a loss in endometrial carcinoma is associated with epithelial-to-mesenchymal transition and a potential for PI3Kinase inhibition. Virchows Archiv. S18-S18.
  • Show author(s) 2012. A discordant histological risk classification in preoperative biopsy and hysterectomy specimens in endometrial cancer is reflected in metastatic risk and prognosis. Acta Obstetricia et Gynecologica Scandinavica. 145-146.
Poster
  • Show author(s) 2015. Nasogastric feeding in hyperemesis gravidarum; tube positioning by ward nurse, a pilot study.
  • Show author(s) 2014. Metabolic tumor volume on FDG-PET/CT predicts deep myometrial invasion, lymph node metastases and survival in patients with endometrial carcinoma .
  • Show author(s) 2009. Stathmin is superior to AKT and Phospho-AKT staining to detect PI3Kinase activation and aggressive endometrial cancer.
Academic literature review
  • Show author(s) 2019. Nausea and vomiting of pregnancy and hyperemesis gravidarum. Nature Reviews Disease Primers. 1-17.
  • Show author(s) 2012. Markers for individualised therapy in endometrial carcinoma. The Lancet Oncology. E353-E361.

More information in national current research information system (CRIStin)